Why the ResApp (ASX:RAP) share price is sinking 5% today

The ResApp (ASX: RAP) share price is sinking today despite a positive announcement made to the ASX market. Here's the latest.

| More on:
falling asx share price represented by woman making sad face

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResApp Health Ltd (ASX: RAP) share price is sinking today. This comes after the company announced that Medgate had started European trails for ResAppDx, its smartphone-based acute respiratory diagnostic test.

At the time of writing, the digital health company's shares are down 6.78%, trading at 5.5 cents.

First, a quick take on Medgate

Founded in 1999, Medgate provides telehealth services, bringing physicians to patients where needed via digital health bookings.

The company operates Europe's largest telemedical centre in Switzerland and employs more than 500 people worldwide. Medgate has a presence in Germany, the Philippines, the United Arab Emirates, and India.

Why is the ResApp share price moving?

In today's release, ResApp advised that Medgate has begun a 3-month pilot trial of ResAppDx through its telemedicine services in Switzerland. This follows a joint development and pilot agreement the companies signed in November last year.

During the initial phase of the partnership, both companies conducted detailed technical reviews on the ResAppDx technology. This included creating roadmaps for patients with respiratory disease symptoms, usability testing, automated processes, and training material development.

The companies will jointly evaluate the ResAppDx platform rollout across Medigate's telehealth service. Several key metrics will be applied as a benchmark to test its success.

They will finalise negotiations on the cost model of the integration once ResAppDx passes the pilot trial.

Management commentary

ResApp CEO and managing director, Dr Tony Keating, commented:

…We are very confident that ResAppDx will provide considerable benefits for Medgate patients, physicians and insurers.

Medgate has made a strong commitment to ResApp and both parties remain confident of a successful pilot trial. The company has already significantly benefitted from Medgate's knowledge and insights into telehealth best practice, and we look forward to continuing this work into the future.

Medgate CEO, Dr Andy Fisher, added:

We are absolutely convinced that the use of new technologies like ResAppDx will enable an advancement of our Digital Health platform. This will benefit our patients by enabling them to be treated conclusively by phone or video in even more cases.

ResApp share price review

The ResApp share price has been a weak performer over the past 12 months, declining more than 65%. The company's shares hit a multi-year low of 5.2 cents last month and are within striking distance today, at 5.5 cents.

Should you invest $1,000 in Resapp Health right now?

Before you buy Resapp Health shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Resapp Health wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

The letters ETF with a man pointing at it.
Share Market News

3 fantastic ASX ETFs to buy with $1,000

These funds could be worth considering if you have money to invest in the share market.

Read more »

Businessman smiles with arms outstretched after receiving good news.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a wonderful Wednesday session for investors today.

Read more »

Two male ASX 200 analysts stand in an office looking at various computer screens showing share prices.
Broker Notes

Macquarie tips 20% upside for this ASX 200 industrials stock

Let's see what the broker is saying about this stock following an update.

Read more »

A man with a wide, eager smile on his face holds up three fingers.
Gold

3 reasons this ASX 200 gold mining giant could soar higher into 2026

A leading expert forecasts more outperformance from this surging ASX 200 gold stock.

Read more »

A young woman lifts her red glasses with one hand as she takes a closer look at news about interest rates rising and one expert's surprising recommendation as to which ASX shares to buy
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A man in a suit smiles at the yellow piggy bank he holds in his hand.
Bank Shares

CBA shares hit a new $176 record high. Too late to buy?

What can stop this bank now?

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why James Hardie, Mayne Pharma, Nufarm, and Resimac shares are falling today

These shares are having a tough time on hump day. But why?

Read more »

Person pointing at an increasing blue graph which represents a rising share price.
Share Gainers

Why Adriatic Metals, Catapult, Seek, and TechnologyOne shares are racing higher today

These shares are having a good time on hump day. But why?

Read more »